Exploration of eJaculatory Anatomy Concept Study (EJAC Study)

NCT ID: NCT05650853

Last Updated: 2023-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-12

Study Completion Date

2023-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ejaculatory dysfunctions (ED) are an important cause of postoperative dissatisfaction, which lead to a decrease in the intensity of orgasms in 50% of patients. ED is a cause for concern for almost a third of patients who need surgery. Surgical techniques have been developed to limit the occurrence of postoperative ED, but their results remain heterogeneous.

There are very few studies on the biomechanical anatomy of ejaculation. Ejaculation is a complex phenomenon involving different structures and in particular the Veru Montanum. This is the key element in the emission of ejaculate within the prostatic urethra. In addition, there is a structure located in the resection zone of the prostate adenoma. It has therefore been suggested that its resection was a primary source of ED.

A single observational study carried out in by Gil Vernet et al in 1994 evaluated on a single healthy 18-year-old volunteer the ejaculatory mechanism of expulsion using an endorectal probe recording the movements of the prostate, the bladder neck and of the proximal urethra during ejaculation.

A contemporary study of the biomechanics of the ejaculatory expulsion phase could confirm and improve understanding of the involvement of anatomical structures. The results of our study aim to adapt surgical techniques aimed at limiting the risk of postoperative ED.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ejaculatory Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study intervention

Transrectal ultrasound and Urethroscopy

Group Type EXPERIMENTAL

Transrectal ultrasound

Intervention Type OTHER

Examinations for observation of the pre, per and post-ejaculatory phases

Urethroscopy

Intervention Type OTHER

Examinations for observation of the pre, per and post-ejaculatory phases

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transrectal ultrasound

Examinations for observation of the pre, per and post-ejaculatory phases

Intervention Type OTHER

Urethroscopy

Examinations for observation of the pre, per and post-ejaculatory phases

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Affiliated subject or beneficiary of a social security scheme
* Subject agreeing to participate and having signed the free, informed consent.

Exclusion Criteria

* Subject with ejaculatory dysfunction
* Subject with urinary dysfunction
* History of urinary or penile surgery
* Subject with untreated urinary tract infection
* History of chronic prostatitis
* Pathology making it impossible to introduce the endorectal probe or the ureteroscope
* History of colorectal inflammatory disease
* Recent intake (within 30 days) of drugs known to interfere with ejaculation
* History of intolerance or allergy to any of the drugs used in the study
* Subject participating in another clinical study
* Adults under guardianship, curatorship or other legal protection; deprived of liberty by judicial or administrative decision; Hospitalized without consent.
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinique Pasteur

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Vincent Misrai

Principal Investigator, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin Pradère, MD

Role: STUDY_DIRECTOR

Clinique La Croix du Sud

Eric Bruguière, MD

Role: STUDY_DIRECTOR

Clinique Pasteur

Vincent Misraï, MD

Role: STUDY_DIRECTOR

Clinique Pasteur

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Pasteur

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01594-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.